SG11202004746VA - Antibodies of increased affinity for the epidermal growth factor receptor and its derived fragments - Google Patents

Antibodies of increased affinity for the epidermal growth factor receptor and its derived fragments

Info

Publication number
SG11202004746VA
SG11202004746VA SG11202004746VA SG11202004746VA SG11202004746VA SG 11202004746V A SG11202004746V A SG 11202004746VA SG 11202004746V A SG11202004746V A SG 11202004746VA SG 11202004746V A SG11202004746V A SG 11202004746VA SG 11202004746V A SG11202004746V A SG 11202004746VA
Authority
SG
Singapore
Prior art keywords
antibodies
growth factor
factor receptor
epidermal growth
increased affinity
Prior art date
Application number
SG11202004746VA
Other languages
English (en)
Inventor
Cabado Yaima Tundidor
Dorantes Getrudis Rojas
Monzón Kalet León
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of SG11202004746VA publication Critical patent/SG11202004746VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202004746VA 2017-11-28 2018-11-20 Antibodies of increased affinity for the epidermal growth factor receptor and its derived fragments SG11202004746VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2017000148A CU24558B1 (es) 2017-11-28 2017-11-28 Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
PCT/CU2018/050004 WO2019105492A1 (es) 2017-11-28 2018-11-20 Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidérmico y sus fragmentos derivados

Publications (1)

Publication Number Publication Date
SG11202004746VA true SG11202004746VA (en) 2020-06-29

Family

ID=64959051

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004746VA SG11202004746VA (en) 2017-11-28 2018-11-20 Antibodies of increased affinity for the epidermal growth factor receptor and its derived fragments

Country Status (16)

Country Link
US (1) US11718676B2 (ja)
EP (1) EP3719037A1 (ja)
JP (1) JP7396992B2 (ja)
KR (1) KR102708617B1 (ja)
CN (1) CN111417654B (ja)
AR (1) AR113843A1 (ja)
AU (1) AU2018377764B2 (ja)
BR (1) BR112020010075A2 (ja)
CA (1) CA3082759A1 (ja)
CU (1) CU24558B1 (ja)
EA (1) EA202091328A1 (ja)
MX (1) MX2020005490A (ja)
SG (1) SG11202004746VA (ja)
TW (1) TWI820058B (ja)
WO (1) WO2019105492A1 (ja)
ZA (1) ZA202003866B (ja)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
SI1859793T1 (sl) 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
US20110256142A1 (en) * 2007-09-06 2011-10-20 Genmab A/S Novel methods and antibodies for treating cancer
KR20130096731A (ko) * 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP2822970A1 (en) 2012-03-08 2015-01-14 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CA2885315C (en) 2012-10-12 2020-06-23 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015164594A1 (en) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
CN104530237B (zh) * 2014-12-31 2017-09-05 百泰生物药业有限公司 抗Her1的治疗性抗体
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
MY188446A (en) * 2015-07-27 2021-12-09 Innocimab Pte Ltd Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)

Also Published As

Publication number Publication date
WO2019105492A1 (es) 2019-06-06
TW201932485A (zh) 2019-08-16
EP3719037A1 (en) 2020-10-07
AU2018377764A1 (en) 2020-07-09
US11718676B2 (en) 2023-08-08
US20210002375A1 (en) 2021-01-07
CN111417654A (zh) 2020-07-14
NZ765527A (en) 2024-02-23
AR113843A1 (es) 2020-06-17
AU2018377764B2 (en) 2022-09-29
KR102708617B1 (ko) 2024-09-25
CA3082759A1 (en) 2019-06-06
KR20200090236A (ko) 2020-07-28
JP7396992B2 (ja) 2023-12-12
MX2020005490A (es) 2020-09-03
CU20170148A7 (es) 2019-07-04
BR112020010075A2 (pt) 2020-10-13
TWI820058B (zh) 2023-11-01
EA202091328A1 (ru) 2020-09-17
CN111417654B (zh) 2023-11-10
CU24558B1 (es) 2021-12-08
JP2021504484A (ja) 2021-02-15
ZA202003866B (en) 2022-06-29

Similar Documents

Publication Publication Date Title
IL272218A (en) ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
IL275073A (en) Antibodies against TREM2 and related methods
EP3621642A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES
IL272274A (en) Antibodies 4H-7B methods for their use
IL278924A (en) Antibodies specific to GUCY2C and their uses
LT3618863T (lt) Anti-tigit antikūnai ir jų panaudojimo būdai
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
IL271696A (en) Agonist antibodies that bind human CD137 and their use
IL273402A (en) Antibodies against human leukocyte antigens type A2 and methods of using them
EP3472200A4 (en) ANTI-MYOSTATIN ANTIBODIES AND METHOD FOR USE
EP3728323A4 (en) ANTI-FZD ANTIBODIES AND METHODS OF USE
EP3684819A4 (en) ANTI-YKL40 ANTIBODIES AND METHODS OF USE
EP3710589A4 (en) ANTI-C1S ANTIBODIES AND METHODS OF USE
EP3630046A4 (en) ANTI-DOUBLECORTIN-LIKE-KINASE-1-ANTIBODY AND METHOD OF APPLICATION
ZA202003858B (en) Monoclonal antibodies and methods for using same
ZA201805051B (en) Egfl6 specific monoclonal antibodies and methods of their use
EP3642231A4 (en) ANTI-VISTA ANTIBODIES AND METHODS OF USE
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
EP3574010A4 (en) ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
SG11202004746VA (en) Antibodies of increased affinity for the epidermal growth factor receptor and its derived fragments
EP3606965A4 (en) ANTI-MASP-1 ANTIBODIES AND METHODS OF USE